Rabies: all 114 studies
Page 2 of 2. Open to participants first (15), then studies with results posted, then the rest; newest registration first within each.
- Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies VaccineCompletedNCT01339312Phase 3
- Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy AdultsCompletedNCT01228383Phase 2
- Persistence of Rabies Antibody 1-5 Years After the Post-exposure Prophylaxis With Vero Cell Antirabies Vaccine and Antibody Response to a Single Booster DoseStatus unknownNCT01173302Phase 4
- Immunogenicity and Safety Study of A New Chromatographically Purified Vero Cell Rabies Vaccine With ID Regimen and ERIGCompletedNCT01137045Phase 4
- Early Rabies Vaccine Immunization in Primary School ChildrenCompletedNCT01107275Phase 3
- Single Center, Open Label, Follow up Study in Subjects Who Previously Received Rabies Vaccine as Simulated Post-Exposure RegimenTerminatedNCT01067079
- Rabies Immune Plasma Booster StudyCompletedNCT01063140
- Study of Purified Vero Rabies Vaccine Serum Free Compared With Reference Purified Vero Rabies Vaccine in Healthy AdultsCompletedNCT00948272Phase 2
- Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and AdolescentsCompletedNCT00708084Phase 2
- Rabies Immunization Concomitant With JEV in ChildrenCompletedNCT00703521Phase 2
- Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in ToddlersCompletedNCT00694460Phase 2
- A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult SubjectsCompletedNCT00656097Phase 2
- Purified Rabies Vaccine for Human Use (Chick-embryo Cell)CompletedNCT00345319Phase 3
- Immunogenicity and Safety of Verorab™ in Indian PopulationCompletedNCT00260351Phase 4